AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17414400 — intervention group
Group type: COMPARATOR
Intervention: Norwegian parent vaccine (25 microg/dose) administered at 0, 6, and 12 weeks
Number of subjects: 332
Study 17414400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 332
Study 15826227 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects moving at different speeds (manipulated speed of objects)
Number of subjects: 0
Study 15826227 — intervention group
Group type: EXPERIMENTAL
Intervention: Scene undergoing translation, zoom, rotation, or combinations of these motions
Number of subjects: 0
Study 15826227 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference with observers' ability to see a coherent scene (moving objects at different speeds and distorting perception of 3-D space)
Number of subjects: 0
Study 11953964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 195
Study 11953964 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD with or without prednisolone
Number of subjects: 195
Study 11596586 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery
Number of subjects: 69
Study 11596586 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 69
Study 9172212 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked presentation of words
Number of subjects: 60
Study 9172212 — intervention group
Group type: COMPARATOR
Intervention: Random presentation of words
Number of subjects: 60
Study 9172212 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked presentation of pictures
Number of subjects: 60
Study 9172212 — intervention group
Group type: COMPARATOR
Intervention: Random presentation of pictures
Number of subjects: 60
Study 8170449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and dietary hygiene instructions (Group 1: 492 children)
Number of subjects: 1475
Study 8170449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and dietary hygiene instructions + fluoro-prophylactic treatment (Group 2: 501 children)
Number of subjects: 1475
Study 8170449 — intervention group
Group type: COMPARATOR
Intervention: No instructions or treatment (Control Group 3: 482 children)
Number of subjects: 1475
Study 2832935 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide + unprocessed bran (50 mg b.i.d. from May to September)
Number of subjects: 73
Study 2832935 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed bran (40 g daily)
Number of subjects: 73
Study 29152828 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR/GZR + RBV
Number of subjects: 70
Study 29152828 — intervention group
Group type: COMPARATOR
Intervention: GZR + RBV
Number of subjects: 70
Study 29152828 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR/GZR
Number of subjects: 70
Study 25628299 — intervention group
Group type: EXPERIMENTAL
Intervention: NYU Caregiver Intervention for Adult Children (NYUCI‐AC)
Number of subjects: 107
Study 25628299 — intervention group
Group type: COMPARATOR
Intervention: Contact control group
Number of subjects: 107
Study 25912760 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual gait training plus kinematic feedback
Number of subjects: 24
Study 25912760 — intervention group
Group type: COMPARATOR
Intervention: Usual gait training
Number of subjects: 24
Study 23097006 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary 2:1 bipolar/unipolar mode (group B)
Number of subjects: 44
Study 23097006 — intervention group
Group type: COMPARATOR
Intervention: Primary 4:1 bipolar/unipolar mode (group A)
Number of subjects: 44
Study 20803854 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid preload anaesthesia (20 mL/kg lactated Ringer's solution)
Number of subjects: 62
Study 20803854 — intervention group
Group type: COMPARATOR
Intervention: No preload anaesthesia
Number of subjects: 62
Study 20803854 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid preload anaesthesia
Number of subjects: 62
Study 19808296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (selective pulmonary vasodilator)
Number of subjects: 100
Study 19808296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16772327 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (8.3 g/day)
Number of subjects: 33
Study 16772327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 14526887 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Focused Grief Therapy (FFGT)
Number of subjects: 81
Study 14526887 — intervention group
Group type: COMPARATOR
Intervention: Family Relationships Index (FRI)
Number of subjects: 81
Study 14526887 — intervention group
Group type: COMPARATOR
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 81
Study 14526887 — intervention group
Group type: COMPARATOR
Intervention: Brief Symptom Inventory (BSI)
Number of subjects: 81
Study 14526887 — intervention group
Group type: COMPARATOR
Intervention: Social Adjustment Scale (SAS)
Number of subjects: 81
Study 11071165 — intervention group
Group type: EXPERIMENTAL
Intervention: Small‐incision cholecystectomy
Number of subjects: 200
Study 11071165 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 200
Study 8791240 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan s.c.
Number of subjects: 66
Study 8791240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 1612732 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherule vaccine
Number of subjects: 37
Study 1612732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1612732 — intervention group
Group type: EXPERIMENTAL
Intervention: Coccidioidomycosis patients
Number of subjects: 37
Study 1612732 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 37
Study 1612732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without evident coccidioidomycosis
Number of subjects: 37
Study 1612732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with histoplasmosis
Number of subjects: 37
Study 31629546 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers according to NLST criteria
Number of subjects: 1601
Study 31629546 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers according to NELSON criteria
Number of subjects: 1601
Study 31629546 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers according to NLST criteria
Number of subjects: 1601
Study 31629546 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers according to NELSON criteria
Number of subjects: 1601
Study 31629546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependence measured with the brief Fagerström test
Number of subjects: 1601
Study 29383698 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion method TOV
Number of subjects: 40
Study 29383698 — intervention group
Group type: COMPARATOR
Intervention: Standard auto-fill method TOV
Number of subjects: 40
Study 26467209 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 464
Study 26467209 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 464
Study 26467209 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP3174
Number of subjects: 464
Study 26467209 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 464
Study 26467209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole
Number of subjects: 464
Study 26467209 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 464
Study 23331874 — intervention group
Group type: EXPERIMENTAL
Intervention: ipulse personal home-use intense pulsed light (IPL) device, treated once weekly for four consecutive weeks
Number of subjects: 10
Study 23331874 — intervention group
Group type: COMPARATOR
Intervention: Control site (contralateral axilla)
Number of subjects: 10
Study 22802542 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe somatic dysfunction in the lumbar region
Number of subjects: 455
Study 22802542 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe somatic dysfunction in the sacrum/pelvis region
Number of subjects: 455
Study 22802542 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of key lesions
Number of subjects: 455
Study 20847105 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 100 μg/day
Number of subjects: 133
Study 20847105 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 μg/day
Number of subjects: 133
Study 20847105 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1,000 μg/day
Number of subjects: 133
Study 20847105 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2,000 μg/day
Number of subjects: 133
Study 20847105 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation in participants with low serum folate (<4.5 ng/mL)
Number of subjects: 133
Study 20847105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 18665698 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Control Treatment (PCT)
Number of subjects: 35
Study 18665698 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational Supportive Treatment (PE-SUP)
Number of subjects: 35
Study 16879670 — intervention group
Group type: EXPERIMENTAL
Intervention: Suburethral sling
Number of subjects: 49
Study 16879670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sling)
Number of subjects: 49
Study 12641643 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training (PT)
Number of subjects: 10
Study 12641643 — intervention group
Group type: COMPARATOR
Intervention: Strength training (ST)
Number of subjects: 10
Study 12641643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PT and ST
Number of subjects: 10
Study 10661332 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (ifosfamide, etoposide, high-dose methotrexate, cisplatin, cytarabine)
Number of subjects: 158
Study 10661332 — intervention group
Group type: COMPARATOR
Intervention: Immediate postoperative radiotherapy with vincristine followed by maintenance chemotherapy (cisplatin, CCNU, vincristine)
Number of subjects: 158
Study 10661332 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (arm I)
Number of subjects: 158
Study 10661332 — intervention group
Group type: COMPARATOR
Intervention: Immediate postoperative radiotherapy (arm II)
Number of subjects: 158
Study 9051202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg)
Number of subjects: 40
Study 9051202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg)
Number of subjects: 40
Study 9051202 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg)
Number of subjects: 40
Study 9051202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8339829 — intervention group
Group type: EXPERIMENTAL
Intervention: Subzonal insemination (SUZI)
Number of subjects: 48
Study 8339829 — intervention group
Group type: COMPARATOR
Intervention: Normal insemination
Number of subjects: 48
Study 2871951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 6
Study 2871951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29264729 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + RSD
Number of subjects: 69
Study 29264729 — intervention group
Group type: COMPARATOR
Intervention: PVI + spironolactone
Number of subjects: 69
Study 26892409 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2771
Study 26892409 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 2771
Study 24326604 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid PCR
Number of subjects: 300
Study 24326604 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 22781725 — intervention group
Group type: EXPERIMENTAL
Intervention: IM + IFN
Number of subjects: 155
Study 20350693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 200
Study 20350693 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous diuretics (IV)
Number of subjects: 200
Study 20350693 — intervention group
Group type: COMPARATOR
Intervention: Bolus diuretics
Number of subjects: 200
Study 17967134 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 38
Study 17967134 — intervention group
Group type: COMPARATOR
Intervention: Calcium 1 g/d and vitamin D 800 UI/d
Number of subjects: 38
Study 15984982 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg neostigmine
Number of subjects: 13
Study 15984982 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg neostigmine + 0.4 mg glycopyrrolate
Number of subjects: 13
Study 15984982 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 13
Study 12712026 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution
Number of subjects: 530
Study 12712026 — intervention group
Group type: COMPARATOR
Intervention: Running tap water
Number of subjects: 530
Study 10711322 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed formulary
Number of subjects: 0
Study 10711322 — intervention group
Group type: COMPARATOR
Intervention: Open formulary
Number of subjects: 0
Study 7474041 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.9% carbohydrate-electrolyte solution (CHO)
Number of subjects: 9
Study 1849786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cisplatin at 70 mg/m2 i.v. on day 1 and etoposide at 100 mg/m2 i.v. on day 1 and 200 mg/m2 orally on days 2 and 3)
Number of subjects: 87
Study 1849786 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 87
Study 6891844 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin
Number of subjects: 0
Study 6891844 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study 6891844 — intervention group
Group type: COMPARATOR
Intervention: Combination of different cytostatic drugs
Number of subjects: 0
Study 6891844 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern chemotherapy with cisplatin
Number of subjects: 0
Study 6891844 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 31134601 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical simulation teaching course
Number of subjects: 392
Study 31134601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 392
Study 28054322 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/d for 5 days)
Number of subjects: 30
Study 28054322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28054322 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 30
Study 28054322 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (responders only)
Number of subjects: 30
Study 28054322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (responders only)
Number of subjects: 30
Study 28054322 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation and Placebo
Number of subjects: 30
Study 25756173 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose intake (≥ 10 E%)
Number of subjects: 1062
Study 25756173 — intervention group
Group type: COMPARATOR
Intervention: Low sucrose intake (< 10 E%)
Number of subjects: 1062
Study 23789911 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 24
Study 23789911 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g glucose
Number of subjects: 24
Study 23789911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21208479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=102)
Number of subjects: 102
Study 21208479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=144 for canteen analysis)
Number of subjects: 102
Study 20122586 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.125 mg/kg loading infusion followed by 0.04 mg/kg/min infusion)
Number of subjects: 30
Study 20122586 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (saline group)
Number of subjects: 30
Study 17717930 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaobai Decoction (XBD)
Number of subjects: 85
Study 17717930 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with magnesium sulfate
Number of subjects: 85
Study 14586719 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25 to 100 mg/day)
Number of subjects: 86
Study 14586719 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 to 5 mg/day)
Number of subjects: 86
Study 14586719 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 86
Study 14586719 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 86
Study 10776007 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg slow-release aspirin (Disprin CV) daily
Number of subjects: 216
Study 10776007 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 216
Study 8924063 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg twice daily
Number of subjects: 207
Study 8924063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 1579511 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral bacteriotherapy using a combination of anaerobe fecal Lactobacilli
Number of subjects: 40
Study 1579511 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral bacteriotherapy using a combination of anaerobe fecal Lactobacilli
Number of subjects: 40
Study 3898417 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine at night
Number of subjects: 43
Study 3898417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31236796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration hypoxic exposure group (HWBV; n=9)
Number of subjects: 19
Study 31236796 — intervention group
Group type: COMPARATOR
Intervention: Vibration normoxic exposure group (NWBV; n=10)
Number of subjects: 19
Study 29855447 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps muscle fatigue group (n=15)
Number of subjects: 45
Study 29855447 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf muscles fatigue group (n=15)
Number of subjects: 45
Study 29855447 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 45
Study 27030303 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized yoga intervention
Number of subjects: 101
Study 27030303 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 101
Study 24661055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions that provided experience with counterstereotypical exemplars
Number of subjects: 17021
Study 24661055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions using evaluative conditioning methods
Number of subjects: 17021
Study 24661055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions providing strategies to override biases
Number of subjects: 17021
Study 24661055 — intervention group
Group type: COMPARATOR
Intervention: Interventions engaging participants with others' perspectives
Number of subjects: 17021
Study 24661055 — intervention group
Group type: COMPARATOR
Intervention: Interventions asking participants to consider egalitarian values
Number of subjects: 17021
Study 24661055 — intervention group
Group type: COMPARATOR
Intervention: Interventions inducing a positive emotion
Number of subjects: 17021
Study 24661055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions invoking high self-involvement
Number of subjects: 17021
Study 24661055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions linking Black people with positivity and White people with negativity
Number of subjects: 17021
Study 24661055 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 17021
Study 22847373 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental plus ketamine (0.5 mg/kg)
Number of subjects: 24
Study 22847373 — intervention group
Group type: COMPARATOR
Intervention: Thiopental alone
Number of subjects: 24
Study 22847373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Thiopental alone and Thiopental plus ketamine)
Number of subjects: 24
Study 20535265 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 120
Study 20535265 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 120
Study 18018805 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary medical care (cumulative number of visits: 0, 1, >= 2)
Number of subjects: 298
Study 18018805 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary medical care (>= 2 visits)
Number of subjects: 298
Study 16148375 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus enalapril (10‐20 mg/day)
Number of subjects: 31
Study 16148375 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus Accupro (slow titration from 5 to a maximum 20 mg/day)
Number of subjects: 31
Study 16148375 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (glycosides, diuretics, peripheral vasodilators)
Number of subjects: 31
Study 12115175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg/day
Number of subjects: 212
Study 12115175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 800 mg/day
Number of subjects: 212
Study 12115175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 1200 mg/day
Number of subjects: 212
Study 12115175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) levels
Number of subjects: 212
Study 12115175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisdesethylchloroquine (BDCQ) levels
Number of subjects: 212
Study 10471564 — intervention group
Group type: COMPARATOR
Intervention: Heparin (10 U/ml)
Number of subjects: 117
Study 10471564 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and Vancomycin (10 U/ml and 25 microg/ml)
Number of subjects: 117
Study 8742262 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory for spatial frequency measured in separate blocks of trials
Number of subjects: 0